
    
      Reduced intensity conditioning regimen of Busulfan (Bu) and Fludarabine (Flu) +
      Anti-Thymocyte Globulin (ATG ) (unrelated donors only) or reduced toxicity conditioning
      regimen of Bu/Flu/alemtuzumab, or reduced hepatic toxicity regimen of melphan/Flu/alemtuzumab
      and AlloSCT, followed by Gemtuzumab Ozogamicin consolidation in patients with average risk
      AML/MDS meeting eligibility criteria.
    
  